Yvonne Greenstreet

Chief Executive Officer & Director, Alnylam

Search every verified Yvonne Greenstreet interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Yvonne Greenstreet, CEO and director of Alnylam, recently participated in a discussion with Jakob Uszkoreit, CEO and co-founder of Inceptive, about the companies' strategic collaboration to apply artificial intelligence to RNAi drug discovery. During the conversation, Greenstreet expressed enthusiasm for the partnership, citing Inceptive's foundational models and Alnylam's rich siRNA dataset as complementary assets. She emphasized Alnylam's longstanding focus on rational drug design and described the collaboration as an opportunity to accelerate the discovery and development of medicines for patients. Greenstreet also highlighted shared values between the two companies, including a passion for patients, entrepreneurial spirit, and determination to advance drug discovery. She noted that Alnylam's scientists approach problems with a firm belief in developing models and processes to understand disease more deeply, aiming to design medicines that go beyond current human capabilities. The discussion framed the partnership as a first step in a long journey toward transformative applications of AI in therapeutics.